[go: up one dir, main page]

SI20026B - Heptapeptidni analogi - antagonisti oksitocina - Google Patents

Heptapeptidni analogi - antagonisti oksitocina Download PDF

Info

Publication number
SI20026B
SI20026B SI9720076A SI9720076A SI20026B SI 20026 B SI20026 B SI 20026B SI 9720076 A SI9720076 A SI 9720076A SI 9720076 A SI9720076 A SI 9720076A SI 20026 B SI20026 B SI 20026B
Authority
SI
Slovenia
Prior art keywords
abu
asn
ile
mpa
ch2oh
Prior art date
Application number
SI9720076A
Other languages
English (en)
Slovenian (sl)
Other versions
SI20026A (sl
Inventor
Per Melin
Anders Nilsson
Jerzy Trojnar
Carl-Johan Aurell
Pierre Riviere
Robert Haigh
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of SI20026A publication Critical patent/SI20026A/sl
Publication of SI20026B publication Critical patent/SI20026B/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/16Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SI9720076A 1996-11-26 1997-11-21 Heptapeptidni analogi - antagonisti oksitocina SI20026B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue
PCT/SE1997/001968 WO1998023636A1 (fr) 1996-11-26 1997-11-21 Analogues d'heptapeptide oxytocine

Publications (2)

Publication Number Publication Date
SI20026A SI20026A (sl) 2000-02-29
SI20026B true SI20026B (sl) 2000-06-30

Family

ID=20404757

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9720076A SI20026B (sl) 1996-11-26 1997-11-21 Heptapeptidni analogi - antagonisti oksitocina

Country Status (34)

Country Link
US (1) US6143722A (fr)
EP (1) EP0938496B1 (fr)
JP (1) JP3405460B2 (fr)
KR (1) KR100463132B1 (fr)
CN (1) CN1129606C (fr)
AR (1) AR008531A1 (fr)
AT (1) ATE242264T1 (fr)
AU (1) AU713424B2 (fr)
BR (1) BR9713366B1 (fr)
CA (1) CA2272990C (fr)
CZ (1) CZ299532B6 (fr)
DE (1) DE69722651T2 (fr)
DK (1) DK0938496T3 (fr)
EE (1) EE03832B1 (fr)
ES (1) ES2203823T3 (fr)
HR (1) HRP970630B1 (fr)
HU (1) HU228568B1 (fr)
IL (1) IL129519A (fr)
LT (1) LT4650B (fr)
LV (1) LV12350B (fr)
MY (1) MY125555A (fr)
NO (1) NO321380B1 (fr)
NZ (1) NZ336445A (fr)
PL (1) PL189292B1 (fr)
PT (1) PT938496E (fr)
RO (1) RO120772B1 (fr)
RU (1) RU2180668C2 (fr)
SE (1) SE9604341D0 (fr)
SI (1) SI20026B (fr)
SK (1) SK283800B6 (fr)
TR (1) TR199901028T2 (fr)
UA (1) UA54459C2 (fr)
WO (1) WO1998023636A1 (fr)
ZA (1) ZA9710518B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
EP1480998B1 (fr) * 2002-02-27 2006-11-22 Ferring BV Intermediaires et procedes destines a fabriquer des analogues d'oxytocine heptapeptide
WO2003093816A2 (fr) * 2002-05-02 2003-11-13 Bayer Healtchare Ag Diagnostics et therapeutiques pour lutter contre des maladies associees au recepteur de l'oxytocine (oxtr)
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
ATE301990T1 (de) * 2003-07-25 2005-09-15 Ferring Bv Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung
ATE324869T1 (de) * 2003-11-13 2006-06-15 Ferring Bv Blisterverpackung und feste dosierungsform enthaltend desmopressin
EP1555029A1 (fr) 2004-01-19 2005-07-20 Ferring B.V. Utilisation de substances à activité oxytocique pour la préparation de médicaments destinés au traitement de l'hypertension
US20060171909A1 (en) * 2005-02-03 2006-08-03 The Procter & Gamble Company Cosmetic compositions comprising colorants with low free dye
SE0600482L (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
WO2009021007A1 (fr) 2007-08-06 2009-02-12 Serenity Pharmaceuticals Corporation Procédés et dispositifs pour l'administration de médicament desmopressine
JP5539310B2 (ja) * 2008-03-31 2014-07-02 フェリング ベスローテン フェンノートシャップ オキシトシン類似体
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
CA2724653A1 (fr) 2008-05-21 2009-11-26 Ferring International Center S.A. Desmopressine orodispersible augmentant la periode initiale de sommeil non perturbe par la nycturie
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
CA2804966A1 (fr) 2010-07-15 2012-01-19 Oleg Iliich Epshtein Procede d'augmentation de l'effet d'une forme activee-potentialisee d'un anticorps
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
EP2684888B1 (fr) 2011-03-09 2019-05-15 Jitsubo Co., Ltd. Nouveau peptide réticulé contenant une structure réticulée non peptidique, procédé de synthèse de peptides réticulés et nouveau composé organique utilisé dans le procédé
CN102875650B (zh) * 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 巴卢西班的制备方法
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
EP3501533B1 (fr) * 2014-12-22 2025-07-09 Ferring B.V. Obe001 pour utiliser le traitement en implantation et grossesse chez les femmes suivant des technologies de reproduction assistée
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
JP2018535946A (ja) 2015-10-06 2018-12-06 フェリング・ベー・フェー バルシバン及びその中間体を作製する新規の方法
AU2017205254B2 (en) 2016-01-04 2021-05-20 Xoma (Us) Lcc Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
AU2017300026B2 (en) 2016-07-21 2023-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
KR20220075340A (ko) 2019-09-03 2022-06-08 옵스에파 에스에이 배아 착상을 촉진하고 유산을 예방하기 위한 옥시토신 길항제 투여 요법
EP4103750A1 (fr) 2020-02-10 2022-12-21 ObsEva S.A. Biomarqueurs pour une thérapie par antagoniste du récepteur de l'oxytocine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT89279B (pt) * 1987-12-21 1993-08-31 Sandoz Sa Processo para a preparacao de uma nova forma cristalina de ciclosporinas e de composicoes farmaceuticas que as contem
US5373089A (en) * 1988-09-02 1994-12-13 Northwestern University Oxytocin antagonist
CA2036973A1 (fr) * 1990-02-27 1991-08-28 Mark G. Bock Antagonistes de l'oxytocine, a base d'hexapeptide cyclique
SE9002384D0 (sv) * 1990-07-09 1990-07-09 Ferring Ab Derivat av baklobshormoner
DE4022247A1 (de) * 1990-07-12 1992-01-16 Hoechst Ag Verfahren zur extraktiven abtrennung von 2-alkylthio-5-phenylpyrimidinen aus ihren reaktionsgemischen
SE501678C2 (sv) * 1993-07-13 1995-04-10 Ferring Bv Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE523819C2 (sv) 1994-01-27 2004-05-18 Per-Ingvar Nilsson Accelerationsmunstycke samt metod för dess användning
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
SE503085C2 (sv) 1995-01-25 1996-03-25 Valeo Engine Cooling Ab Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan

Also Published As

Publication number Publication date
HK1022481A1 (en) 2000-08-11
NZ336445A (en) 2000-06-23
IL129519A0 (en) 2000-02-29
HRP970630B1 (en) 2002-04-30
NO992532L (no) 1999-05-26
EP0938496B1 (fr) 2003-06-04
LT99052A (en) 2000-01-25
EE9900210A (et) 1999-12-15
DE69722651D1 (en) 2003-07-10
LT4650B (lt) 2000-04-25
KR20000069045A (ko) 2000-11-25
SI20026A (sl) 2000-02-29
SK70499A3 (en) 2000-10-09
LV12350A (lv) 1999-09-20
NO321380B1 (no) 2006-05-02
EE03832B1 (et) 2002-08-15
HU228568B1 (en) 2013-04-29
CA2272990A1 (fr) 1998-06-04
AU713424B2 (en) 1999-12-02
IL129519A (en) 2004-09-27
AR008531A1 (es) 2000-01-19
AU5142998A (en) 1998-06-22
UA54459C2 (uk) 2003-03-17
PL189292B1 (pl) 2005-07-29
US6143722A (en) 2000-11-07
DE69722651T2 (de) 2004-04-08
CZ299532B6 (cs) 2008-08-27
RO120772B1 (ro) 2006-07-28
CA2272990C (fr) 2002-11-19
RU2180668C2 (ru) 2002-03-20
TR199901028T2 (xx) 1999-07-21
SK283800B6 (sk) 2004-02-03
JP2000507617A (ja) 2000-06-20
EP0938496A1 (fr) 1999-09-01
HRP970630A2 (en) 1998-10-31
MY125555A (en) 2006-08-30
HUP0000577A2 (hu) 2000-11-28
PT938496E (pt) 2003-10-31
KR100463132B1 (ko) 2004-12-23
ZA9710518B (en) 1998-06-10
WO1998023636A1 (fr) 1998-06-04
NO992532D0 (no) 1999-05-26
BR9713366A (pt) 2000-01-25
BR9713366B1 (pt) 2010-05-18
HUP0000577A3 (en) 2001-02-28
JP3405460B2 (ja) 2003-05-12
DK0938496T3 (da) 2003-10-06
SE9604341D0 (sv) 1996-11-26
LV12350B (en) 1999-11-20
ATE242264T1 (de) 2003-06-15
CN1129606C (zh) 2003-12-03
ES2203823T3 (es) 2004-04-16
CN1238781A (zh) 1999-12-15
CZ183299A3 (cs) 2000-05-17

Similar Documents

Publication Publication Date Title
SI20026B (sl) Heptapeptidni analogi - antagonisti oksitocina
RU99113364A (ru) Гептапептидные аналоги окситоцина
AU669856B2 (en) Compositions and methods for the sublingual or buccal administration of therapeutic agents
ES2589915T3 (es) Conjugados de GABA y métodos de utilización de los mismos
KR970042553A (ko) 캠프토테신 유도체
MXPA02005536A (es) Acidos aminopropilfosfinicos novedosos.
DE69912952D1 (en) Cyclosporine
SI2068907T1 (en) Pegylated sugars and glycopeptides are associated with glycerol
EP2130548A3 (fr) Peptides de libération d'hormone de croissance
RU2000100369A (ru) Аналоги пептида лг-рф, их применение и содержащие их фармацевтические композиции
DE69533399T2 (de) Zyklische hexapeptid somatostatin analoga
SI9420001B (sl) Polipeptidni antagonisti bombezina
CA2292846A1 (fr) Analogues de peptides de lh-rh, utilisation de ces derniers et compositions pharmaceutiques les contenant
AR025307A1 (es) Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
CA2097192A1 (fr) Antagonistes de la bombesine
JP2005508842A5 (fr)
JP2019523260A5 (fr)
JPH04502922A (ja) 治療用ペプチド
CA1335622C (fr) Analogues de la bradykinine comprenant une liaison non peptidique
WO2005018657A3 (fr) Analogues de gonadoliberine (gn-rh) non mammaliens et leur utilisation dans la regulation de la fertilite et de la gestation
EP1861127A1 (fr) Chelateurs pour des conjugues radioactivement marques comprenant une chaine laterale stabilisante
WO2005019457A3 (fr) Analogues de la gnrh non mammiferes et leurs applications dans la regulation de la fertilite et de la grossesse
JP2006505556A5 (fr)
CN1126999A (zh) 具有催产素拮抗剂活性的肽类化合物
AR029930A1 (es) Peptidos analogos de la sustancia p, procesos de sintesis de los mismos, composiciones y el uso de dichos peptidos para la manufactura de un medicamento para el tratamiento de cancer

Legal Events

Date Code Title Description
IF Valid on the event date